A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy

被引：0
|
作者：
Grierson, Patrick
Wang-Gillam, Andrea
Park, Haeseong
Pedersen, Katrina
Tan, Benjamin R.
Amin, Manik A.
Suresh, Rama
Trikalinos, Nikolaos
Liu, Jingxia
机构：
[1] Washington Univ, St Louis, MO 63110 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Mayo Sch Grad Med Educ, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS793
引用
收藏
页数：1
相关论文
共 50 条
  • [41] THE COST-EFFECTIVENESS OF LIPOSOMAL IRINOTECAN AND 5-FLUOROURACIL (5-FU)/LEUCOVORIN (LV) FOR THE TREATMENT OF PATIENTS WITH METASTATIC ADENOCARCINOMA OF PANCREAS WHO HAVE PROGRESSED FOLLOWING THE USE OF GEMCITABINE-RELATED THERAPIES IN GREECE
    Gourzoulidis, G.
    Stefanou, G.
    Koulentaki, M.
    Beletsi, A.
    Boukovinas, I
    Karamouzis, M.
    Kourlaba, G.
    VALUE IN HEALTH, 2020, 23 : S442 - S442
  • [42] nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients
    Ueno, Makoto
    Nakamori, Shoji
    Sugimori, Kazuya
    Kanai, Masashi
    Ikeda, Masafumi
    Ozaka, Masato
    Furukawa, Masayuki
    Okusaka, Takuji
    Kawabe, Ken
    Furuse, Junji
    Komatsu, Yoshito
    Ishii, Hiroshi
    Sato, Atsushi
    Shimizu, Satoshi
    Chugh, Priti
    Tang, Rui
    Ioka, Tatsuya
    CANCER MEDICINE, 2020, 9 (24): : 9396 - 9408
  • [43] Subgroup analysis by baseline pain intensity (BPI) and analgesic use (BAU) in NAPOLI-1: A phase III study of liposomal irinotecan (nal IRI)±5-fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Macarulla, Teresa Mercade
    Siveke, Jens T.
    Dean, Andrew Peter
    Hubner, Richard
    Blanc, Jean-Frederic
    Cunningham, David
    Chen, Li-Tzong
    Mirakhur, Beloo
    Chen, Jie
    de Jong, Floris A.
    Wang-Gillam, Andrea
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [44] Phase IV study of first-line bevacizumab plus irinotecan and infusional 5-FU/LV in patients with metastatic colorectal cancer: AVIRI
    Sobrero, A. F.
    Young, S.
    Balcewicz, M.
    Chiarra, S.
    Perez Carrion, R.
    Mainwaring, P.
    Gapski, J.
    Clarke, S.
    Langer, B.
    Ackland, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [45] Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Hubner, R. A.
    Chen, L-T.
    Siveke, J. T.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G. S.
    Macarulla, T.
    Lee, K-H.
    Cunningham, D.
    Blanc, J-F.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    Mamlouk, K.
    Belanger, B.
    de Jong, F.
    von Hoff, D. D.
    Wang-Gillam, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] A PHASE III STUDY COMPARING LAROTAXEL TO 5-FU (CONTINUOUS INTRAVENOUS 5-FU OR CAPECITABINE) IN PATIENTS WITH ADVANCED PANCREATIC CANCER (APC) PREVIOUSLY TREATED WITH A GEMCITABINE CONTAINING REGIMEN
    Van Cutsem, E.
    Macarulla, T.
    Van Laethem, J.
    Couture, F.
    Peeters, M.
    Hoff, Gehn M.
    Roman, L.
    Lequesne, L.
    Charpentier, E.
    Conroy, T.
    ANNALS OF ONCOLOGY, 2010, 21 : 12 - 13
  • [47] A phase 1/2, open -label, dose -expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer
    Wainberg, Z.
    Boland, P.
    Lieu, C.
    Dayyani, F.
    Macarulla, T.
    Zhang, B.
    Belanger, B.
    Moore, Y.
    Wang, T.
    Maxwell, F.
    Dean, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [48] NIFE-trial: Liposomal irinotecan (nal-IRI) plus 5-fluorouracil (5-FU) and leucovorin (LV) or gemcitabine plus cisplatin in advanced biliary-tract cancer: An open label, randomized, multicenter phase II trial of the AIO
    Ettrich, T. J.
    Perkhofer, L.
    Berger, A. W.
    Seufferlein, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [49] Paclitaxel-Based Chemotherapy for Advanced Pancreatic Cancer after Gemcitabine-Based Therapy Failure: A Case Series of 5 Patients
    Igarashi, Hisato
    Ito, Tetsuhide
    Hisano, Terumasa
    Fujimori, Nao
    Niina, Yusuke
    Yasuda, Mikihiko
    Kaku, Toyoma
    Matsuo, Susumu
    Oono, Takamasa
    Yoshinaga, Masahiro
    Sakai, Hiroyuki
    Takayanagi, Ryoichi
    CASE REPORTS IN ONCOLOGY, 2011, 4 (03): : 534 - 541
  • [50] CA19-9 decrease and overall survival (OS) in the NAPOLI-1 trial of liposomal irinotecan (nal-IRI) 6 5-fluorouracil and leucovorin (5-FU/LV) in metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based therapy
    Chen, L-T.
    Wang-Gillam, A.
    Shan, Y-S.
    Mercade, T. Macarulla
    Blanc, J. F.
    Hubner, R.
    Chiu, C-F.
    Schwartsmann, G.
    Siveke, J.
    Belanger, B.
    de Jong, F.
    Mamlouk, K.
    von Hoff, D.
    ANNALS OF ONCOLOGY, 2017, 28
12345